Targeted therapy for aggressive breast cancer
Official title: Crosslinking-based targeted therapy for triple-negative breast cancer
Funded at Arizona State University-Tempe Campus · NIH-10828403 · Data updated 2026-11-12
This study is testing a new treatment for triple-negative breast cancer that uses tiny particles to deliver medicine directly to cancer cells, helping to stop them from spreading and improving how well the treatment works.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arizona State University-Tempe Campus NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project start | April 13, 2023 |
| Project end | September 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $215,376 |
| NIH project number | 5R21CA280458-02 |
| Project ID | NIH-10828403 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who have HER1 and/or HER3 receptor expression.
✕Less likely to help
Patients with other subtypes of breast cancer that do not express HER1 or HER3 may not benefit from this research.
What this research studies
This research focuses on developing a new targeted therapy for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer. The approach involves creating specialized nanoparticles that can bind to cancer cells expressing specific receptors (HER1 and/or HER3). These nanoparticles will deliver anticancer drugs directly to the cancer cells, aiming to prevent their spread and improve treatment outcomes. By crosslinking the cancer cells together, the therapy seeks to inhibit their migration and invasion, which are critical factors in cancer metastasis.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have gone: While targeted therapies for breast cancer have shown promise, this specific crosslinking approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Arizona State University-Tempe Campus
Tempe, United States Active
Researchers
- Principal investigator: Chen, Shengxi — Arizona State University-Tempe Campus
- Study coordinator: Chen, Shengxi
Related research
Other NIH-funded projects on the same topics.
-
PET scans to track glutamine use in triple-negative breast cancer
This project uses special PET scans with an amino-acid tracer to see how triple-negative breast cancers use glutamine so doctors can better match metabolism-targeted treatments to patients.
-
Improving Targeted Therapy for Triple Negative Breast Cancer
This project aims to develop a new way to deliver targeted medicines directly to triple-negative breast cancer tumors using special RNA molecules.
-
Using PET imaging to understand glutamine metabolism in triple-negative breast cancer
This study is looking at how a substance called glutamine affects triple-negative breast cancer to find better ways to treat it, using special imaging to see how much glutamine is in the cancer cells and helping doctors choose the best therapies for patients.
-
Targeted therapy for triple-negative breast cancer using antibody-drug conjugates
This study is working on new treatments for triple-negative breast cancer that aim to target cancer cells directly while being kinder to healthy cells, so patients can have better outcomes with fewer side effects.
-
New treatment approach for triple negative breast cancer using targeted siRNA delivery
This study is testing a new way to deliver a special treatment directly to tumors in patients with triple negative breast cancer, making it easier for the medicine to reach the cancer and potentially improve how well it works.
-
Using nanotechnology to target therapy for triple negative breast cancer
This study is exploring new ways to treat triple negative breast cancer using tiny particles to deliver special molecules that can help stop cancer cells from growing, aiming to create better treatment options that work specifically for this type of cancer and have fewer side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.